Semaglutide Medications Show Promise in Reducing Cardiovascular Events and Kidney Disease Progression
Rapid Read

Semaglutide Medications Show Promise in Reducing Cardiovascular Events and Kidney Disease Progression

What's Happening? Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, has demonstrated significant benefits beyond weight loss and type 2 diabetes management. Large-scale trials, such as the SELECT study involving over 17,000 adults, revealed that semaglutide lowered the risk of major adverse ca
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.